Advanced search
1 file | 69.02 KB

Cancer-related fatigue

STEFANIE DE WAELE (UGent) and Simon Van Belle (UGent)
(2010) ACTA CLINICA BELGICA. 65(6). p.375-382
Author
Organization
Abstract
Cancer-related fatigue (CRF) is the most commonly reported symptom in patients with cancer with a prevalence up to 100%. It has a signifi cant negative impact on quality of life. An effective management of CRF could signifi cantly reduce the disease burden associated with cancer and its treatment. Unfortunately, the underlying pathophysiology is very complex and not uniform. This article reviews the possible therapy of contributing factors, nonpharmacological treatment, such as exercise and psychosocial interventions, and pharmacologic approaches in managing CRF. Numerous drugs, such as psychostimulants (methylphenidate, dexamphetamines, modafi nil and pemoline), antidepressants, corticosteroids, L-carnitine, donepezil and guarana have been studied. Methylphenidate, modafi nil and guarana show the most promising results so far. However, additional randomized, placebo-controlled trials are needed to determine the benefit of these and other drugs in the treatment of CRF.
Keywords
PATIENTS RECEIVING CHEMOTHERAPY, PROPOSED DIAGNOSTIC-CRITERIA, pharmacotherapy, management, PLACEBO-CONTROLLED TRIAL, RANDOMIZED CLINICAL-TRIAL, DOUBLE-BLIND TRIAL, QUALITY-OF-LIFE, BREAST-CANCER, RADIATION-THERAPY, PHASE-III, DEPRESSION, fatigue, cancer

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 69.02 KB

Citation

Please use this url to cite or link to this publication:

Chicago
DE WAELE, STEFANIE, and Simon Van Belle. 2010. “Cancer-related Fatigue.” Acta Clinica Belgica 65 (6): 375–382.
APA
DE WAELE, S., & Van Belle, S. (2010). Cancer-related fatigue. ACTA CLINICA BELGICA, 65(6), 375–382.
Vancouver
1.
DE WAELE S, Van Belle S. Cancer-related fatigue. ACTA CLINICA BELGICA. 2010;65(6):375–82.
MLA
DE WAELE, STEFANIE, and Simon Van Belle. “Cancer-related Fatigue.” ACTA CLINICA BELGICA 65.6 (2010): 375–382. Print.
@article{1123648,
  abstract     = {Cancer-related fatigue (CRF) is the most commonly reported symptom in patients with cancer with a prevalence up to 100\%. It has a signifi cant negative impact on quality of life. An effective management of CRF could signifi cantly reduce the disease burden associated with cancer and its treatment. Unfortunately, the underlying pathophysiology is very complex and not uniform. This article reviews the possible therapy of contributing factors, nonpharmacological treatment, such as exercise and psychosocial interventions, and pharmacologic approaches in managing CRF. Numerous drugs, such as psychostimulants (methylphenidate, dexamphetamines, modafi nil and pemoline), antidepressants, corticosteroids, L-carnitine, donepezil and guarana have been studied. Methylphenidate, modafi nil and guarana show the most promising results so far. However, additional randomized, placebo-controlled trials are needed to determine the benefit of these and other drugs in the treatment of CRF.},
  author       = {DE WAELE, STEFANIE and Van Belle, Simon},
  issn         = {0001-5512},
  journal      = {ACTA CLINICA BELGICA},
  keyword      = {PATIENTS RECEIVING CHEMOTHERAPY,PROPOSED DIAGNOSTIC-CRITERIA,pharmacotherapy,management,PLACEBO-CONTROLLED TRIAL,RANDOMIZED CLINICAL-TRIAL,DOUBLE-BLIND TRIAL,QUALITY-OF-LIFE,BREAST-CANCER,RADIATION-THERAPY,PHASE-III,DEPRESSION,fatigue,cancer},
  language     = {eng},
  number       = {6},
  pages        = {375--382},
  title        = {Cancer-related fatigue},
  volume       = {65},
  year         = {2010},
}

Web of Science
Times cited: